动态风险分层预测儿童分化型甲状腺癌长期结局
该研究纳入176例年龄≤18岁、随访≥5年的儿童分化型甲状腺癌患者,验证动态风险分层(DRS)的预测价值。随访2年内DRS将患者分为极好反应82/176(46.6%)、生化不完全反应56/176(31.8%)和结构不完全反应38/176(21.6%)。中位随访10.6年,10年总生存率和无病生存率分别为100%和88.7%;多因素分析中仅DRS与无病生存显著相关(P=0.016)。
要点
- 儿童DTC随访2年内DRS分为极好反应46.6%、生化不完全反应31.8%、结构不完全反应21.6%。
- 10年总生存率100%,10年无病生存率88.7%。
- 多因素分析中仅DRS与无病生存显著相关(P=0.016)。
核心结论
- 与成人相似,DRS能正确预测儿童DTC的长期结局。
- 在ATA初始风险分层基础上,DRS可进一步细化儿童DTC的风险分层,有助于制定更个性化的治疗和随访策略。
研究设计与样本
- 验证性研究,纳入年龄≤18岁、随访≥5年的儿童DTC患者176例,中位诊断年龄15岁。
- 所有患者均接受甲状腺切除术和放射性碘作为初始治疗的一部分。
- 根据随访前2年的临床、生化和影像学检查结果进行DRS分类,分为极好反应、生化不完全反应和结构不完全反应。
- 采用单因素和多因素分析识别影响无病生存(DFS)的因素。
主要发现
- DRS分类:极好反应82/176(46.6%),生化不完全反应56/176(31.8%),结构不完全反应38/176(21.6%)。
- 中位随访10.6年(四分位距7.7-15.5年),10年总生存率和DFS率分别为100%和88.7%。
- 单因素分析中,DFS显著受甲状腺外侵犯(P=0.002)、淋巴结转移(P=0.018)、ATA初始风险分层(P=0.033)和DRS(P=0.004)影响。
- 多因素分析中,仅DRS与DFS显著相关(P=0.016)。
临床怎么用
- 作者认为,在ATA初始风险分层基础上,DRS可进一步细化儿童DTC的风险分层,有助于制定更个性化的治疗和随访策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The American Thyroid Association (ATA) guidelines recommend Dynamic Risk Stratification (DRS) for predicting long-term outcomes and personalizing management in adult differentiated thyroid cancers (DTCs). However, its applicability in pediatric DTCs needs to be validated. OBJECTIVE: We have attempted a validation study concerning the use of DRS in pediatric DTCs. METHODS: Data of children (age ≤18 years) with DTCs and follow-up of ≥5 years were extracted. All patients were classified according to DRS (excellent biochemical or structural incomplete responses). Univariate and multivariate analyses were done to identify factor(s) affecting disease-free survival (DFS). RESULTS: We included 176 pediatric patients with DTC (median age at diagnosis 15 years). All patients underwent thyroidectomy and received radioiodine as part of initial management. On the basis of clinical, biochemical, and imaging findings acquired during the first 2 years of follow-up, the DRS system divided patients into 3 response categories: excellent response in 82/176 (46.6%), biochemical incomplete response in 56/176 (31.8%), and structural incomplete response in 38/176 (21.6%) patients. The median follow-up was 10.6 years (interquartile range 7.7-15.5). Ten-year overall survival and DFS rates were 100% and 88.7%, respectively. In univariate analysis, DFS was significantly affected by extrathyroidal extension (P = .002), lymph node metastasis (P = .018), ATA initial risk stratification (P = .033), and DRS (P = .004). However, in multivariate analysis, DRS alone showed a significant association with DFS (P = .016). CONCLUSION: Like adults, DRS correctly predicts long-term outcomes in pediatric DTC. In addition to ATA initial risk stratification, DRS could further refine risk in pediatric DTCs and help in planning more personalized treatment and follow-up strategies.
引用
- Majeed AK, Satapathy S, Ballal S, et al. Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers. J Clin Endocrinol Metab. 2023. PMID: 36577747. doi:10.1210/clinem/dgac731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。